top of page

New Procedures Strengthen Oversight of Medical Device and IVD Supply Interruptions

21 hours ago
4 min read

Regulatory Update | Medical Devices & IVDs | November 2026


France has introduced additional procedures to strengthen the management of anticipated supply interruptions involving certain medical devices and in vitro diagnostic devices (IVDs).


Decree No. 2026-730 of 1 August 2026 was published in the French Official Journal on 4 August 2026 and entered into force on 5 August 2026. It sets out practical procedures for the measures the French National Agency for the Safety of Medicines and Health Products (ANSM) can take when supply interruptions or discontinuations could threaten continuity of patient care.


The decree builds on the EU's existing framework under Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR), as amended by Regulation (EU) 2024/1860. For manufacturers and authorised representatives operating in France, it brings greater clarity on notification channels, information requirements, and response obligations when product availability is at risk.


Why Was the Decree Introduced?


Device and IVD availability is essential to healthcare continuity. Interruptions to products used in critical diagnostic or treatment pathways can put patients at risk and create serious challenges for healthcare providers.


To address this, the EU introduced Article 10a into both the MDR and IVDR through Regulation (EU) 2024/1860. Under it, manufacturers must:


  • Inform the competent authority in the Member State where they or their authorised representative are established when they anticipate an interruption or discontinuation that could reasonably be expected to cause serious harm, or a risk of serious harm, to patients or public health

  • Provide that information at least six months in advance, except in exceptional circumstances

  • Inform the economic operators, healthcare institutions, and healthcare professionals they directly supply


France's decree adds national procedures for applying this framework and managing the resulting risks.


What Does the Decree Establish?


Formal Notification Procedures

Under the new provisions of the French Public Health Code:


  • Information must be sent to ANSM electronically, following procedures set by the Agency's Director General.

  • Economic operators, healthcare institutions, and healthcare professionals must be informed through a method that provides evidence of receipt.


The notification must identify the affected device and include:


  • Device name, class, and intended indication

  • Commercial designation

  • Manufacturer's name

  • Reasons for the anticipated interruption or discontinuation

  • Estimated duration of the interruption


These requirements apply to the relevant devices and IVDs under the respective EU frameworks. The aim is to give the authority and affected stakeholders enough detail to assess consequences and prepare responses.


Clarity on ANSM's Powers


The decree also sets procedural safeguards for how ANSM exercises its powers. Before certain regulatory decisions, the affected party must be able to submit written observations and, on request, oral observations:


Circumstance

Minimum Period for Observations

Ordinary

Not shorter than 8 days

Urgent

May be reduced to 24 hours


The French Public Health Code also empowers ANSM to take measures that are strictly necessary and proportionate to maintain continuity of patient care. Depending on the situation, these may include:


  • Publishing information about the anticipated interruption

  • Issuing recommendations on alternative solutions

  • Imposing specific conditions or restrictions on activities involving the device


Such measures may concern distribution, placing on the market, export, advertising, making available, or use. Decisions are published on the Agency's website.


Manufacturer and Authorised Representative Responsibilities


Manufacturers (or their authorised representatives) must respond to ANSM requests for additional information within 8 days or 24 hours in urgent cases.


That makes internal coordination critical. Know who your responsible regulatory contacts are, be able to retrieve relevant supply information quickly, and keep communication arrangements with distributors, healthcare institutions, and healthcare professionals organised enough to support timely notification and follow-up.


What Companies Should Do


1. Review product exposure: Identify devices that could fall within the interruption or discontinuation notification requirements, especially where unavailability could cause serious harm to patients or public health.


2. Strengthen notification procedures: Set up clear internal processes for communicating anticipated interruptions to ANSM and relevant stakeholders.


3. Prepare essential information: Make sure you can accurately provide product identification, classification, intended indication, manufacturer details, reasons for interruption, and estimated duration.


4. Establish response responsibilities: Assign personnel to manage ANSM information requests and ensure the 8-day and 24-hour deadlines can be met.


5. Review supply-chain communication: Confirm distributors and other economic operators can pass interruption information on to the healthcare institutions and professionals they supply.


These steps improve preparedness and reduce regulatory and operational risk during a supply disruption.


ARQon Insight


Decree No. 2026-730 highlights the growing importance of supply continuity as part of device and IVD compliance.


Regulatory obligations no longer stop at registration, conformity assessment, and market entry. Manufacturers must also be ready to manage situations that could affect the continued availability of essential healthcare products.


For companies supplying France, the practical challenge is making sure regulatory reporting, stakeholder communication, and internal decision-making work together when supply risks emerge. Early preparation helps manufacturers and their authorised representatives respond to regulatory requests more effectively while supporting continuity of patient care.


Key Takeaway


Decree No. 2026-730 establishes clearer procedures for managing anticipated interruptions or discontinuations involving certain devices and IVDs. By specifying notification channels, information requirements, procedural safeguards, and response deadlines, it strengthens the practical implementation of the EU supply-continuity framework.


For manufacturers and authorised representatives, effective regulatory communication and supply-risk management are essential to meeting these obligations.

Plan for supply disruption before it happens, not after the first request from the regulator.


How ARQon Can Support You


At ARQon, we support healthcare companies navigating evolving international requirements with:


  • Regulatory intelligence

  • Market-entry strategy

  • Regulatory compliance planning

  • Cross-border market access


Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.


Official Sources

Regulatory note: The French decree establishes national implementation procedures for the relevant MDR and IVDR supply-interruption framework. The underlying EU notification obligations apply to qualifying anticipated interruptions or discontinuations that could result in serious harm or a risk of serious harm to patients or public health.

Comments


bottom of page